JANX Quote, Financials, Valuation and Earnings

EyePoint Plc has a net margin of -243.13% compared to Janux Therapeutics, Inc.'s net margin of -6183.44%. Janux Therapeutics, Inc.'s return on equity of -10.94% beat EyePoint Plc's return on equity of -79.15%.

Janux Therapeutics, Inc. has a consensus price target of $63.71, signalling upside risk potential of 387.05%. On the other hand EyePoint Plc has an analysts' consensus of $36.08 which suggests that it could grow by 135.38%. Given that Janux Therapeutics, Inc. has higher upside potential than EyePoint Plc, analysts believe Janux Therapeutics, Inc. is more attractive than EyePoint Plc.

Janux Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison EyePoint Plc has a beta of 1.758, suggesting its more volatile than the S&P 500 by 75.759%.

Janux Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EyePoint Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics, Inc. pays -- of its earnings as a dividend. EyePoint Plc pays out -- of its earnings as a dividend.

Janux Therapeutics, Inc. quarterly revenues are $10M, which are larger than EyePoint Plc quarterly revenues of $966K. Janux Therapeutics, Inc.'s net income of -$24.3M is higher than EyePoint Plc's net income of -$59.7M. Notably, Janux Therapeutics, Inc.'s price-to-earnings ratio is -- while EyePoint Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics, Inc. is 79.31x versus 24.84x for EyePoint Plc. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals, Inc. has a net margin of -243.13% compared to Janux Therapeutics, Inc.'s net margin of -82.06%. Janux Therapeutics, Inc.'s return on equity of -10.94% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Janux Therapeutics, Inc. has a consensus price target of $63.71, signalling upside risk potential of 387.05%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $91.63 which suggests that it could grow by 10.19%. Given that Janux Therapeutics, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Janux Therapeutics, Inc. is more attractive than Ionis Pharmaceuticals, Inc..

Janux Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.94%.

Janux Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Janux Therapeutics, Inc. quarterly revenues are $10M, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Janux Therapeutics, Inc.'s net income of -$24.3M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Janux Therapeutics, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics, Inc. is 79.31x versus 14.16x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -243.13% compared to Janux Therapeutics, Inc.'s net margin of 34.4%. Janux Therapeutics, Inc.'s return on equity of -10.94% beat Eli Lilly & Co.'s return on equity of 104.39%.

Janux Therapeutics, Inc. has a consensus price target of $63.71, signalling upside risk potential of 387.05%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,211.21 which suggests that it could grow by 19.98%. Given that Janux Therapeutics, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Janux Therapeutics, Inc. is more attractive than Eli Lilly & Co..

Janux Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.

Janux Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.62% to investors and pays a quarterly dividend of $1.73 per share. Janux Therapeutics, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Janux Therapeutics, Inc. quarterly revenues are $10M, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Janux Therapeutics, Inc.'s net income of -$24.3M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Janux Therapeutics, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 44.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics, Inc. is 79.31x versus 14.11x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

MannKind Corp. has a net margin of -243.13% compared to Janux Therapeutics, Inc.'s net margin of 9.72%. Janux Therapeutics, Inc.'s return on equity of -10.94% beat MannKind Corp.'s return on equity of --.

Janux Therapeutics, Inc. has a consensus price target of $63.71, signalling upside risk potential of 387.05%. On the other hand MannKind Corp. has an analysts' consensus of $9.61 which suggests that it could grow by 73.49%. Given that Janux Therapeutics, Inc. has higher upside potential than MannKind Corp., analysts believe Janux Therapeutics, Inc. is more attractive than MannKind Corp..

Janux Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison MannKind Corp. has a beta of 0.839, suggesting its less volatile than the S&P 500 by 16.131%.

Janux Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics, Inc. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.

Janux Therapeutics, Inc. quarterly revenues are $10M, which are smaller than MannKind Corp. quarterly revenues of $82.1M. Janux Therapeutics, Inc.'s net income of -$24.3M is lower than MannKind Corp.'s net income of $8M. Notably, Janux Therapeutics, Inc.'s price-to-earnings ratio is -- while MannKind Corp.'s PE ratio is 58.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics, Inc. is 79.31x versus 5.45x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.